Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution

Panitumumab (Pmab) is generally considered to be ineffective after the failure of cetuximab (Cmab) therapy in metastatic colorectal cancer (mCRC) patients. However, a few studies have demonstrated that Pmab is an effective treatment for disease progression following Cmab-based regimens in the USA. I...

Descripción completa

Detalles Bibliográficos
Autores principales: SONODA, HIROMICHI, MEKATA, EIJI, SHIMIZU, TOMOHARU, ENDO, YOSHIHIRO, TANI, TOHRU
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628964/
https://www.ncbi.nlm.nih.gov/pubmed/23599789
http://dx.doi.org/10.3892/ol.2013.1171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628964/
https://www.ncbi.nlm.nih.gov/pubmed/23599789
http://dx.doi.org/10.3892/ol.2013.1171

Ejemplares similares